ARCHIVES

Pertuzumab Delays Progression In HER2-Positive Breast Cancer

This article is from The Cancer Letter archive.

Vol. 34 No. 8 | August 26, 2011

Download PDF Visit The Full Archive

Related Articles

American Association for Cancer Research Presents Awards at 2012 Annual Meeting

April 6, 2012

St. John’s Wort Not Indicated For Patients On Irinotecan

May 31, 2002

$1.5 Million In Direct Costs Is Proposed Core Grant Requirement

July 12, 1991

ODAC Calls For Tougher Standards For Accelerated Approval In Oncology

February 11, 2011

Cancer Control Progress, Challenge Mark ACS Observance

October 18, 1991

Program Project Scores Have Compressed Review Shuld Return To Rank Order; Broder

October 2, 1992